Wall Street Zen Upgrades Ekso Bionics (NASDAQ:EKSO) to Hold

Ekso Bionics (NASDAQ:EKSO) was upgraded by Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ekso Bionics in a report on Monday, December 8th. HC Wainwright set a $6.00 price objective on Ekso Bionics and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $115.50.

Ekso Bionics Price Performance

NASDAQ:EKSO opened at $4.67 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The business’s 50-day moving average price is $4.78 and its 200 day moving average price is $4.17. Ekso Bionics has a 52-week low of $2.73 and a 52-week high of $14.97. The firm has a market cap of $12.24 million, a P/E ratio of -0.82 and a beta of 0.82.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.45. The company had revenue of $4.23 million during the quarter, compared to the consensus estimate of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. As a group, sell-side analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Scott G. Davis sold 23,315 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the transaction, the chief executive officer owned 78,777 shares of the company’s stock, valued at approximately $378,129.60. This trade represents a 22.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jerome Wong sold 11,288 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $54,182.40. Following the sale, the chief financial officer directly owned 26,009 shares in the company, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Ekso Bionics

Hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in Ekso Bionics during the 3rd quarter valued at about $198,000. Virtu Financial LLC acquired a new stake in shares of Ekso Bionics during the third quarter worth approximately $57,000. Shay Capital LLC purchased a new position in Ekso Bionics during the third quarter valued at approximately $67,000. Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics in the 3rd quarter valued at approximately $333,000. Finally, Armistice Capital LLC lifted its position in Ekso Bionics by 18.4% in the 1st quarter. Armistice Capital LLC now owns 2,042,382 shares of the company’s stock worth $823,000 after buying an additional 316,733 shares in the last quarter. 6.42% of the stock is owned by hedge funds and other institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.